* To whom correspondence should be addressed.
# These authors contributed equally to the work.
Received: June 1, 2026; Revised: October 5, 2026; Accepted: October 5, 2026
The STING signaling pathway is a key regulatory mechanism of the innate immune response that coordinates the recognition of foreign double-stranded DNA molecules in the cytoplasm and participates in the regulation of numerous cellular processes associated with carcinogenesis. Modulation of this cascade is considered a promising approach to the treatment of infectious and autoimmune diseases, as well as various malignancies. By analyzing RNA-sequencing data, we demonstrated that STING/TMEM173 expression is elevated in acute myeloid leukemia cells and is an unfavorable prognostic factor for patients with this diagnosis. One potential STING agonist is 10-carboxymethyl-9-acridanone/acridone acetic acid (CMA), whose effect on this pathway has been demonstrated in murine cells, but not in human cells. CMA is an active component of immunostimulatory drugs registered in the Russian Federation. Analysis of the effects of CMA on KG-1 and K562 human myeloid leukemia cells demonstrated that CMA upregulated the expression of STING, TBK1, IRF3, IRF7, and STING-dependent inflammatory mediators, with this effect being most pronounced in K562 cells. According to the data obtained, CMA-treated K562 cells exhibited a more intense induction of genes regulating the mitochondrial apoptotic pathway. This finding was also consistent with a more pronounced decrease in the viability of K562 cells compared with KG-1 cells treated with CMA. Analysis of combinations with antitumor drugs showed that CMA antagonized the cytotoxic activity of doxorubicin and cisplatin, but exhibited pronounced synergy when combined with the Bcl-2 inhibitor venetoclax. The obtained data indicate that CMA can be considered a potential STING agonist in human cells in vitro at high concentrations; however, its therapeutic potential, molecular mechanisms of action, efficacy, and safety require careful preclinical and clinical evaluation.
KEY WORDS: cGAS-STING signaling pathway, STING agonist, acridone acetic acid (CMA), acute myeloid leukemia (AML), synergy, venetoclax, innate immunity, type I interferon, combined antitumor therapy, apoptosisDOI: 10.1134/S0006297926601772
Publisher’s Note. Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.